BULETIN BIL 1/2017

POMs

TPN

ADR

Pensijilan 5S

PRP Kontrak

FAQ

Welcome & Farewell

Editorial Board Advisor

Pn Hjh Rohayah Binti

Abd Ghani

Chief Editors

Pn Roslita Binti Alivi

Pn Tan Pei Li

Pn Shafika Hanim

Pn Nurul Balqis Riza

Cik Sharifah Sadiqa

Editors

Aminur Anuar

Ahmad Khidir

Chan Shu Ting

Cheah Cui Yi

Diana Wong

Parenteral nutrition therapy is defined as therapeutic intravenous administration of nutrients such as amino acids, glu-

cose, lipids, electrolytes, vitamins and trace elements to a patient when oral or enteral nutrition is inadequate (due to poor

absorption), impossible (due to bowel obstruction) or undesirable (due to deep coma or necessity for bowel rest). It can be

Definition of Parenteral Nutrition (PN)

PN products available in Pharmacy Department, HSI

Total Parenteral Nutrition

Total parenteral nutrition (TPN) Partial parenteral nutrition (PPN)

Refers to situation where the patient’s complete

nutritional needs (all macro and micronutrients) are cov-

ered by PN, and in which nutrition is not given by any

route other than intravenously

Refers to situation where nutrition is provided in ad-

dition to parenteral nutrition by any route other than

intravenously. For example, when the oral or enteral

tube routes cannot independently achieve the defined

nutritional care plan target

Table 1: Examples of pre-mixed PN available for adults.

Types of Parenteral Nutrition (PN)

Product name

SmofKabiven® Nutriflex® Lipid

SmofKabiven®

Central

SmofKabiven®

Peripheral

Nutriflex®

Lipid Peri

Nutriflex®

Lipid Special

Route Central

Central/

Peripheral

Central/

Peripheral Central

Volume (ml) 1477 1448 ml 1875 625

Total energy, (kcal) 1600 1000 1435 740

Amino acids (g) 75 46 60 36

Nitrogen (g) 12 7.4 9 5

Taurine (g) 0.75 0.46 - -

Glucose (g) 187 103 120 90

Lipids (g) 56 41 75 25

Fish oil, rich in omega-3-acids (g) 8.4 6.1 - -

Non-protein calories (kcal) 1300 800 1195 598

Ration energy from glucose: lipid 58:42 50:50 40:60 60:40

Osmolarity 1500 850 840 1545

ADVERSE DRUG REACTION

Olanzapine: Risk of Drug Reaction with Eosinophilia and

Systemic Symptoms (DRESS)

Since year 2000, the NPRA has received 283

ADR reports with 488 adverse events

suspected to be related to olanzapine.

There were four reports (0.8%) involving se-

vere cutaneous adverse reactions (SCARs),

In Hospital Sultan Ismail Johor Bahru, there

were one case reported on 2016.

Patient develop bilateral leg swelling and facial

swelling after taking T.olanzapine 5 mg.

The U.S. FDA is warning that the antipsychotic

medicine olanzapine can cause a rare but seri-

ous skin reaction that can progress to affect

other parts of the body. We are adding a new

warning to the drug labels for all olanzapine-

containing products that describes this severe

condition known as Drug Reaction with Eosin-

ophilia and Systemic Symptoms (DRESS)

DRESS is used to describe a severe drug hyper-

sensitivity eruption associated with constitu-

tional symptoms, such as fever, malaise,

A review of the FDA Adverse Event Reporting

System (FAERS) revealed 23 cases of DRESS as-

sociated with olanzapine use

The median dose of olanzapine was reported

If DRESS is suspected, stop treatment with olanzapine. Management of DRESS includes early

recognition of the symptoms, discontinuation of the offending drug and supportive care.

Advise patients taking olanzapine to seek medical attention if they experience the

following symptoms: fever, rash, swollen lymph glands, or face swelling.

Local Report Global Report

Report in HSIJB

Advices

Pensijilan 5S Ke arah Pensijilan 5S pada tahun 2017

Audit Pensijilan 5S oleh wakil MPC pada 28 Februari 2017

Farmasi Logistik

Farmasi Pesakit Luar Farmasi Pesakit Dalam

‘Semoga Amalan 5S memastikan suasana bekerja yang kondusif dan teratur’

Aktiviti 5S oleh JK farmasi:

Countdown

Hari Sisih

Permainan dan quiz

Tahniah kepada Jabatan Farmasi HSIJB kerana berjaya mendapatkan Pensijilan

5S untuk tempoh 1 tahun (28 Feb 2017—27 Feb 2018)

Zon Winter

Zon Summer Zon Autumn

Zon Summer

Perubahan Zon: Inovasi

“Kerana kekangan jawatan tetap, Kerajaan mengambil keputusan melantik secara kontrak kumpulan pertama

graduan perubatan, pergigian dan farmasi selewat-lewatnya Disember 2016.” – Ucapan Bajet 2017

PRP KONTRAK

Tidak mengisi jawatan

Pelantikan secara kontrak bertujuan: Latihan Siswazah dan/atau Khidmat Wajib

Tarikh kuatkuasa: 1 Disember 2016

Tempoh kontrak yang diluluskan:

Dasar Pelantikan Kontrak

Skim/ Jawatan Tempoh Maksima Jumlah

Keseluruhan Latihan Siswazah Khidmat Wajib

Pegawai Farmasi

Gred UF41

2 tahun 1 tahun 3 tahun

1. Tamat pengajian

2. Permohonan Sijil Pendaftaran dengan Lembaga Farmasi Malaysia

3. Permohonan Suruhanjaya Perkhidmatan Awam (SPA)

4. Hadir Temuduga oleh SPA

5. Permohanan penempatan melalui system e-Pharmacist

6. MenyedIa dan melengkapkan Borang PerjanjIan dan Dokumen Pelantikan Kontrak

7. Lapor diri menghadiri Program Transformasi Minda (PTM)

8. Lapor diri bertugas di hospital

Latar Belakang

Proses Pelantikan Kontrak

•Memenuhi tahap kesihatan

•Memenuhi syarat lantikan seperti dalam skim perkhidmatan

•Mempunyai tatakelakuan yang memuaskan

Syarat Pelantikan

•Telah menjalani pemeriksaaan kesihatan •Membuat Akuan Berkanun

•Telah tandatangani Surat Aku Janji •Mengisi borang dan lulus Tapisan

Keselamatan

Syarat

Pelantikan

Pertama

Syarat

Pelantikan

Tetap

Syarat

Pelantikan

Semula

•Pelantikan mengikut susunan merit

•Menjalani dengan jayanya latihan siswazah/ memenuhi syarat khidmat wajib dan syarat pengesahan dalam perkhidmatan:

1. Syarat minimum tempoh percubaan selama 1 tahun

2. Hadir dengan jaya ProgramTransfromasi Minda (PTM)

3. Perakuan Ketua Jabatan/ Ketua perkhidmatan

4. Prestasi sekurang-kurangnya purata 85%